je.st
news
Tag: phase
Onxeo S.A.: Phase II trial results of Validive presented at the ASCO Conference
2015-04-02 18:23:24| Logistics - Topix.net
Regulatory News: Onxeo S.A. , an innovative company specializing in the development of orphan oncology drugs, today announced that Validive phase II clinical trial results have been accepted for a poster presentation at the 2015 Annual Meeting of the American Society of Clinical Oncology . The ASCO annual meeting is a major event in the field of oncology that brings together 30,000 health professionals and updates on the major latest steps and results achieved in oncology worldwide.
Tags: the
results
presented
trial
Phase 1 Issues Framework
2015-04-02 00:21:08| PortlandOnline
Draft Task Force recommendations PDF Document, 786kbCategory: Phase 1 Recommendations (March 31)
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302
2015-04-01 08:23:10| drugdiscoveryonline Home Page
Therapure Innovations, a division of Therapure Biopharma Inc., recently announces that the U.S. Food and Drug Administration (FDA) has given the company approval to proceed with a Phase 1 clinical trial of TBI 302, a targeted therapeutic for the treatment of liver cancer
Tags: trial
phase
approval
cancer
Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Clinical Trial Data
2015-04-01 07:37:14| drugdiscoveryonline Home Page
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases recently announced that data from the Company’s Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting
Baxter BioScience Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophilia A And B Patients With Inhibitors
2015-04-01 07:33:48| drugdiscoveryonline Home Page
Baxter International Inc. recently announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors
Tags: with
results
iii
positive
Sites : [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] next »